Overview of Delphi process participation by multidisciplinary group of stakeholders
| Stakeholder group . | Ballot 1 . | Ballot 2 . | Ballot 3 . | |||
|---|---|---|---|---|---|---|
| Ballot completion . | Discussion attendance . | Ballot completion . | Discussion attendance . | Ballot completion . | Discussion attendance . | |
| No. (%) . | No. (%) . | No. (%) . | No. (%) . | No. (%) . | No. (%) . | |
| People living with cancer and family members (n = 7) | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 6 (85.7) |
| Clinicians and other clinical staff (n = 19)a | 17 (89.5) | 17 (89.5) | 19 (100) | 15 (78.9) | 17 (89.5) | 11 (57.9) |
| Institutional leaders (n = 19)b | 18 (94.7) | 14 (77.8) | 17 (94.4) | 11 (61.1) | 19 (100) | 9 (47.4) |
| Improvement leaders (n = 9) | 8 (88.9) | 4 (44.4) | 9 (100) | 7 (77.8) | 9 (100) | 7 (77.8) |
| Researchers (n = 16)c | 16 (100) | 13 (81.3) | 15 (93.8) | 15 (93.8) | 16 (100) | 13 (81.3) |
| Policy makers and funders (n = 7) | 7 (100) | 4 (57.1) | 5 (71.4) | 3 (42.9) | 5 (71.4) | 3 (42.9) |
| Total participants (n = 77) | 73 (94.8) | 59 (76.6) | 72 (93.5) | 58 (75.3) | 73 (94.8) | 49 (63.6) |
| Stakeholder group . | Ballot 1 . | Ballot 2 . | Ballot 3 . | |||
|---|---|---|---|---|---|---|
| Ballot completion . | Discussion attendance . | Ballot completion . | Discussion attendance . | Ballot completion . | Discussion attendance . | |
| No. (%) . | No. (%) . | No. (%) . | No. (%) . | No. (%) . | No. (%) . | |
| People living with cancer and family members (n = 7) | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 6 (85.7) |
| Clinicians and other clinical staff (n = 19)a | 17 (89.5) | 17 (89.5) | 19 (100) | 15 (78.9) | 17 (89.5) | 11 (57.9) |
| Institutional leaders (n = 19)b | 18 (94.7) | 14 (77.8) | 17 (94.4) | 11 (61.1) | 19 (100) | 9 (47.4) |
| Improvement leaders (n = 9) | 8 (88.9) | 4 (44.4) | 9 (100) | 7 (77.8) | 9 (100) | 7 (77.8) |
| Researchers (n = 16)c | 16 (100) | 13 (81.3) | 15 (93.8) | 15 (93.8) | 16 (100) | 13 (81.3) |
| Policy makers and funders (n = 7) | 7 (100) | 4 (57.1) | 5 (71.4) | 3 (42.9) | 5 (71.4) | 3 (42.9) |
| Total participants (n = 77) | 73 (94.8) | 59 (76.6) | 72 (93.5) | 58 (75.3) | 73 (94.8) | 49 (63.6) |
Clinicians and other clinical staff included the following subgroups: physicians (n = 12) and clinical staff (eg, nursing, social work, chaplaincy) (n = 7).
Institutional leaders included subgroups: system or cancer center leaders (n = 10) and Clinical Oncology Group practice leaders (n = 9).
Researchers included subgroups: clinician researchers (n = 8) and nonclinician researchers (n = 8).
Overview of Delphi process participation by multidisciplinary group of stakeholders
| Stakeholder group . | Ballot 1 . | Ballot 2 . | Ballot 3 . | |||
|---|---|---|---|---|---|---|
| Ballot completion . | Discussion attendance . | Ballot completion . | Discussion attendance . | Ballot completion . | Discussion attendance . | |
| No. (%) . | No. (%) . | No. (%) . | No. (%) . | No. (%) . | No. (%) . | |
| People living with cancer and family members (n = 7) | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 6 (85.7) |
| Clinicians and other clinical staff (n = 19)a | 17 (89.5) | 17 (89.5) | 19 (100) | 15 (78.9) | 17 (89.5) | 11 (57.9) |
| Institutional leaders (n = 19)b | 18 (94.7) | 14 (77.8) | 17 (94.4) | 11 (61.1) | 19 (100) | 9 (47.4) |
| Improvement leaders (n = 9) | 8 (88.9) | 4 (44.4) | 9 (100) | 7 (77.8) | 9 (100) | 7 (77.8) |
| Researchers (n = 16)c | 16 (100) | 13 (81.3) | 15 (93.8) | 15 (93.8) | 16 (100) | 13 (81.3) |
| Policy makers and funders (n = 7) | 7 (100) | 4 (57.1) | 5 (71.4) | 3 (42.9) | 5 (71.4) | 3 (42.9) |
| Total participants (n = 77) | 73 (94.8) | 59 (76.6) | 72 (93.5) | 58 (75.3) | 73 (94.8) | 49 (63.6) |
| Stakeholder group . | Ballot 1 . | Ballot 2 . | Ballot 3 . | |||
|---|---|---|---|---|---|---|
| Ballot completion . | Discussion attendance . | Ballot completion . | Discussion attendance . | Ballot completion . | Discussion attendance . | |
| No. (%) . | No. (%) . | No. (%) . | No. (%) . | No. (%) . | No. (%) . | |
| People living with cancer and family members (n = 7) | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 7 (100) | 6 (85.7) |
| Clinicians and other clinical staff (n = 19)a | 17 (89.5) | 17 (89.5) | 19 (100) | 15 (78.9) | 17 (89.5) | 11 (57.9) |
| Institutional leaders (n = 19)b | 18 (94.7) | 14 (77.8) | 17 (94.4) | 11 (61.1) | 19 (100) | 9 (47.4) |
| Improvement leaders (n = 9) | 8 (88.9) | 4 (44.4) | 9 (100) | 7 (77.8) | 9 (100) | 7 (77.8) |
| Researchers (n = 16)c | 16 (100) | 13 (81.3) | 15 (93.8) | 15 (93.8) | 16 (100) | 13 (81.3) |
| Policy makers and funders (n = 7) | 7 (100) | 4 (57.1) | 5 (71.4) | 3 (42.9) | 5 (71.4) | 3 (42.9) |
| Total participants (n = 77) | 73 (94.8) | 59 (76.6) | 72 (93.5) | 58 (75.3) | 73 (94.8) | 49 (63.6) |
Clinicians and other clinical staff included the following subgroups: physicians (n = 12) and clinical staff (eg, nursing, social work, chaplaincy) (n = 7).
Institutional leaders included subgroups: system or cancer center leaders (n = 10) and Clinical Oncology Group practice leaders (n = 9).
Researchers included subgroups: clinician researchers (n = 8) and nonclinician researchers (n = 8).
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
